New York, United States, December 2024 – Kyle R. has assumed the role of Chief Financial Officer (CFO) at Lexeo Therapeutics, a clinical-stage genetic medicines company headquartered in New York City. In his new role, Kyle will oversee the company’s financial strategy and operations, contributing to the advancement of Lexeo’s transformative gene therapy programs targeting cardiovascular diseases and APOE4-associated Alzheimer’s disease.
Before joining Lexeo Therapeutics, Kyle served as Chief Business Officer at Zentalis Pharmaceuticals, a NASDAQ-listed biopharmaceutical company, where he led strategic business operations for one year. During his tenure, he played a pivotal role in shaping the company’s growth and business development initiatives.
Prior to Zentalis, Kyle was the Managing Director and Portfolio Manager at Eventide Asset Management for nearly two years, where he led the healthcare investment team and co-managed the firm’s public mutual fund, achieving top-decile performance.
Earlier, Kyle spent over four years as a Managing Partner at Pappas Capital, where he focused on life sciences venture capital, supporting groundbreaking innovations and companies in the healthcare sector.
Kyle also gained significant experience as a Pharma and Biotechnology Equity Research Analyst at T. Rowe Price for more than four years. In this role, he managed major pharmaceutical and biotech investments, developing financial models and strategies that drove institutional investment success.
His career in financial and strategic advisory began at Cowen Inc., where he served as a Vice President in Pharmaceutical Equity Research, working closely with industry leaders to evaluate pipelines and corporate strategies.
Kyle’s early career included postdoctoral research at the Dana-Farber Cancer Institute and Harvard Medical School, where he contributed to groundbreaking research on treatments for neuromuscular disorders, publishing in prestigious journals such as Cell and Nature.
About Lexeo Therapeutics
Lexeo Therapeutics is a clinical-stage genetic medicines company based in New York City. The company is dedicated to transforming healthcare by leveraging pioneering science and innovative genetic therapies. Drawing on research from institutions like Weill Cornell Medicine and the University of California San Diego, Lexeo is advancing a pipeline targeting cardiovascular diseases and APOE4-associated Alzheimer’s disease. With a leadership team comprised of industry pioneers, Lexeo is committed to delivering breakthroughs in gene therapy to address unmet medical needs.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
